Skip to main content
Top
Published in: Calcified Tissue International 6/2014

01-06-2014 | Original Research

The Relationship Between Proton Pump Inhibitor Adherence and Fracture Risk in the Elderly

Authors: Jian Ding, Debra A. Heller, Frank M. Ahern, Theresa V. Brown

Published in: Calcified Tissue International | Issue 6/2014

Login to get access

Abstract

Studies suggest that long-term use of proton pump inhibitors (PPIs) may be associated with an increased risk of fracture. However, the role of medication adherence in this association is not fully understood. A retrospective cohort study was conducted to examine the relationship between PPI use/adherence and fracture risk among elderly subjects by combining administrative pharmacy claims data, survey data, and Medicare data. The study cohort included 1,604 PPI users and 23,672 nonusers who were enrolled in Pennsylvania’s Pharmaceutical Assistance Contract for the Elderly program. PPI adherence was measured by the proportion of days covered (PDC). Time-dependent Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) of PPI use/adherence for fracture risk while controlling for demographics, comorbidity, body mass index, smoking, and non-PPI medication use. The overall incidence of any fracture per 100 person-years was 8.7 for PPI users and 5.0 for nonusers. A gradient in fracture risk according to PPI adherence was observed. Relative to nonusers, fracture HRs associated with the highest (PDC ≥ 0.80), intermediate (PDC 0.40–0.79), and lowest (PDC <0.40) adherence levels were 1.46 (p < 0.0001), 1.30 (p = 0.02), and 0.95 (p = 0.75), respectively. In addition, the fracture risk of PPI use was significant for hip (HR = 1.32, p = 0.04) and vertebral (HR = 1.69, p = 0.0005) fractures, and risk was similar between major osteoporotic and other fractures. These results provide further evidence that PPI use may increase fracture risk in the elderly and highlight the need for clinicians to periodically reassess elderly patients’ individualized needs for ongoing PPI therapy, while weighing potential risks and benefits.
Literature
2.
go back to reference Budhia S, Mikyas Y, Tang M, Badamgarav E (2012) Osteoporotic fractures: a systematic review of US healthcare costs and resource utilization. Pharmacoeconomics 30:147–170PubMedCrossRef Budhia S, Mikyas Y, Tang M, Badamgarav E (2012) Osteoporotic fractures: a systematic review of US healthcare costs and resource utilization. Pharmacoeconomics 30:147–170PubMedCrossRef
3.
go back to reference Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRef Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRef
4.
go back to reference Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Assessment of fracture risk. Eur J Radiol 71:392–397PubMedCrossRef Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Assessment of fracture risk. Eur J Radiol 71:392–397PubMedCrossRef
5.
go back to reference Cumming RG (1998) Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 12:43–53PubMedCrossRef Cumming RG (1998) Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 12:43–53PubMedCrossRef
6.
go back to reference Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960PubMedCrossRef Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960PubMedCrossRef
7.
go back to reference Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953PubMedCrossRef Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953PubMedCrossRef
8.
go back to reference Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83PubMedCrossRef
9.
go back to reference Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326PubMedCentralPubMedCrossRef Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326PubMedCentralPubMedCrossRef
10.
go back to reference Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259PubMedCentralPubMedCrossRef Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259PubMedCentralPubMedCrossRef
11.
go back to reference de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20:1989–1998PubMedCrossRef de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20:1989–1998PubMedCrossRef
12.
go back to reference Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, Reid DM, Eastell R, Gluer CC (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13–19PubMedCrossRef Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, Reid DM, Eastell R, Gluer CC (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13–19PubMedCrossRef
13.
go back to reference Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139:93–101PubMedCentralPubMedCrossRef Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139:93–101PubMedCentralPubMedCrossRef
14.
go back to reference Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 170:765–771PubMedCrossRef Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 170:765–771PubMedCrossRef
15.
go back to reference Teramura-Grönblad M, Hosia-Randell H, Muurinen S, Pitkala K (2010) Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care 28:154–159PubMedCentralPubMedCrossRef Teramura-Grönblad M, Hosia-Randell H, Muurinen S, Pitkala K (2010) Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care 28:154–159PubMedCentralPubMedCrossRef
16.
go back to reference Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, de Boer A, van Staa T, de Vries F (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 22:903–910PubMedCentralPubMedCrossRef Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, de Boer A, van Staa T, de Vries F (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 22:903–910PubMedCentralPubMedCrossRef
17.
go back to reference Khalili H, Huang ES, Jacobson BC, Camargo CA Jr, Feskanich D, Chan AT (2012) Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 344:e372PubMedCentralPubMedCrossRef Khalili H, Huang ES, Jacobson BC, Camargo CA Jr, Feskanich D, Chan AT (2012) Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 344:e372PubMedCentralPubMedCrossRef
18.
go back to reference Mello M, Weideman RA, Little BB, Weideman MW, Cryer B, Brown GR (2012) Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients. Dig Dis Sci 57:2416–2422PubMedCrossRef Mello M, Weideman RA, Little BB, Weideman MW, Cryer B, Brown GR (2012) Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients. Dig Dis Sci 57:2416–2422PubMedCrossRef
23.
go back to reference Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28:951–959PubMedCrossRef Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28:951–959PubMedCrossRef
24.
go back to reference Chen J, Yuan YC, Leontiadis GI, Howden CW (2012) Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 46:93–114PubMedCrossRef Chen J, Yuan YC, Leontiadis GI, Howden CW (2012) Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 46:93–114PubMedCrossRef
25.
go back to reference Kwok CS, Yeong JK, Loke YK (2011) Meta-analysis: risk of fractures with acid-suppressing medication. Bone 48:768–776PubMedCrossRef Kwok CS, Yeong JK, Loke YK (2011) Meta-analysis: risk of fractures with acid-suppressing medication. Bone 48:768–776PubMedCrossRef
26.
go back to reference Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904PubMedCrossRef Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904PubMedCrossRef
27.
go back to reference Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26:331–342PubMedCrossRef Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26:331–342PubMedCrossRef
30.
go back to reference Leslie WD, Tsang JF, Caetano PA, Lix LM, Manitoba Bone Density Program (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92:77–81PubMedCrossRef Leslie WD, Tsang JF, Caetano PA, Lix LM, Manitoba Bone Density Program (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92:77–81PubMedCrossRef
31.
go back to reference Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL (2009) Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 43:36–44PubMedCrossRef Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL (2009) Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 43:36–44PubMedCrossRef
32.
go back to reference Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740PubMed Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740PubMed
33.
go back to reference Wiens M, Etminan M, Gill SS, Takkouche B (2006) Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260:350–362PubMedCrossRef Wiens M, Etminan M, Gill SS, Takkouche B (2006) Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260:350–362PubMedCrossRef
34.
go back to reference Boyle N, Naganathan V, Cumming RG (2010) Medication and falls: risk and optimization. Clin Geriatr Med 26:583–605PubMedCrossRef Boyle N, Naganathan V, Cumming RG (2010) Medication and falls: risk and optimization. Clin Geriatr Med 26:583–605PubMedCrossRef
35.
go back to reference Bloch F, Thibaud M, Dugue B, Breque C, Rigaud AS, Kemoun G (2011) Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 23:329–346PubMedCrossRef Bloch F, Thibaud M, Dugue B, Breque C, Rigaud AS, Kemoun G (2011) Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 23:329–346PubMedCrossRef
36.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36:8–27PubMedCrossRef Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36:8–27PubMedCrossRef
37.
go back to reference Shtatland ES, Kleinman K, Cain EM (2005) Model building in PROC PHREG with automatic variable selection and information criteria. In: Proceedings of the 30th Annual SAS Users Group International Conference. Paper 206–30. SAS Institute, Cary, NC Shtatland ES, Kleinman K, Cain EM (2005) Model building in PROC PHREG with automatic variable selection and information criteria. In: Proceedings of the 30th Annual SAS Users Group International Conference. Paper 206–30. SAS Institute, Cary, NC
38.
go back to reference Eom CS, Park SM, Myung SK, Yun JM, Ahn JS (2011) Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 9:257–267PubMedCentralPubMedCrossRef Eom CS, Park SM, Myung SK, Yun JM, Ahn JS (2011) Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 9:257–267PubMedCentralPubMedCrossRef
39.
go back to reference Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K (2011) Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 106:1209–1218PubMedCrossRef Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K (2011) Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 106:1209–1218PubMedCrossRef
40.
go back to reference Chia LR, Schlenk EA, Dunbar-Jacob J (2006) Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging 23:191–202PubMedCrossRef Chia LR, Schlenk EA, Dunbar-Jacob J (2006) Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging 23:191–202PubMedCrossRef
41.
go back to reference Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15–18PubMedCentralPubMedCrossRef Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15–18PubMedCentralPubMedCrossRef
42.
go back to reference Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W, CaMos Research Group (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 107:1361–1369PubMedCrossRef Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W, CaMos Research Group (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 107:1361–1369PubMedCrossRef
43.
go back to reference Lau YT, Ahmed NN (2012) Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 32:67–79PubMedCrossRef Lau YT, Ahmed NN (2012) Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 32:67–79PubMedCrossRef
44.
go back to reference Figura N, Gennari L, Merlotti D, Lenzi C, Campagna S, Franci B, Lucani B, Trabalzini L, Bianciardi L, Gonnelli C, Santucci A, Nut A (2005) Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. Dig Dis Sci 50:847–852PubMedCrossRef Figura N, Gennari L, Merlotti D, Lenzi C, Campagna S, Franci B, Lucani B, Trabalzini L, Bianciardi L, Gonnelli C, Santucci A, Nut A (2005) Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. Dig Dis Sci 50:847–852PubMedCrossRef
45.
go back to reference Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565–574PubMedCrossRef Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565–574PubMedCrossRef
Metadata
Title
The Relationship Between Proton Pump Inhibitor Adherence and Fracture Risk in the Elderly
Authors
Jian Ding
Debra A. Heller
Frank M. Ahern
Theresa V. Brown
Publication date
01-06-2014
Publisher
Springer US
Published in
Calcified Tissue International / Issue 6/2014
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-014-9855-6

Other articles of this Issue 6/2014

Calcified Tissue International 6/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.